Abdominal radiology (New York) · 2025
Common bile duct dilatation on MRI in autosomal dominant polycystic kidney disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sattar Usama, Zhu Chenglin, Yin Xiaorui, Luo Xianfu, Bazojoo Vahid, Prince Albert S, Rennert Hanna, Brandman Danielle, Schonfeld Emily, Blumenfeld Jon D, Prince Martin R
Аннотация
PURPOSE: Polycystic liver disease is the most prevalent extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Non-obstructive asymptomatic common bile duct (CBD) dilatation has been observed anecdotally on CT scans, but CT is not optimal for biliary visualization. Here, we measured CBD diameter on T2-weighted MRI in ADPKD subjects to determine if CBD dilatation is associated with ADPKD.
METHODS: CBD diameter was measured retrospectively on ADPKD subjects (n = 254) and on age- and sex-matched controls without ADPKD (n = 254) who underwent abdominal MRI. CBD diameter in these groups was compared and correlated with clinical, laboratory and magnetic resonance imaging (MRI) features, including organ volumes and cyst burden.
RESULTS: CBD median diameter [interquartile range, IQR, 25%, 75%] was 22% larger in ADPKD compared to controls (5.6 [4.7, 6.9] mm vs. 4.6 [3.9, 5.4] mm, p < 0.001). CBD diameter measurements had excellent inter-observer agreement (Intraclass correlation coefficient = 0.92). Thirteen (5.1%) ADPKD subjects had a CBD diameter ≥ 10 mm compared to 1 (0.4%) control subject (p < 0.001). Multivariable analysis found the presence of PKD1 or PKD2 mutation (beta = 1.5, P < 0.001) and age (beta = 0.04, p < 0.001) to be associated with increased CBD diameter and serum albumin associated with decreased CBD diameter (beta=-0.39, p < 0.001).
CONCLUSION: ADPKD subjects had 22% larger CBD diameters than in non-ADPKD controls and were more likely to have CBD dilatation ≥ 10 mm without CBD obstruction. Awareness of this association of non-obstructive CBD dilatation with ADPKD may limit unnecessary diagnostic testing.
METHODS: CBD diameter was measured retrospectively on ADPKD subjects (n = 254) and on age- and sex-matched controls without ADPKD (n = 254) who underwent abdominal MRI. CBD diameter in these groups was compared and correlated with clinical, laboratory and magnetic resonance imaging (MRI) features, including organ volumes and cyst burden.
RESULTS: CBD median diameter [interquartile range, IQR, 25%, 75%] was 22% larger in ADPKD compared to controls (5.6 [4.7, 6.9] mm vs. 4.6 [3.9, 5.4] mm, p < 0.001). CBD diameter measurements had excellent inter-observer agreement (Intraclass correlation coefficient = 0.92). Thirteen (5.1%) ADPKD subjects had a CBD diameter ≥ 10 mm compared to 1 (0.4%) control subject (p < 0.001). Multivariable analysis found the presence of PKD1 or PKD2 mutation (beta = 1.5, P < 0.001) and age (beta = 0.04, p < 0.001) to be associated with increased CBD diameter and serum albumin associated with decreased CBD diameter (beta=-0.39, p < 0.001).
CONCLUSION: ADPKD subjects had 22% larger CBD diameters than in non-ADPKD controls and were more likely to have CBD dilatation ≥ 10 mm without CBD obstruction. Awareness of this association of non-obstructive CBD dilatation with ADPKD may limit unnecessary diagnostic testing.